RecruitingPhase 2NCT06640309

The Effect of Nicotinamide on the Clinical Outcome of Rheumatoid Arthritis Patients

Sponsor

Ain Shams University

Enrollment

70 participants

Start Date

Dec 2, 2023

Study Type

INTERVENTIONAL

Conditions

Rheumatoid Arthritis

Summary

A randomized controlled interventional study to evaluate the efficacy and safety of nicotinamide supplementation in rheumatoid arthritis patients receiving conventional synthetic disease modifying anti-rheumatic drugs.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing whether nicotinamide (a form of vitamin B3) can help improve outcomes for people with rheumatoid arthritis whose disease is not well controlled. **You may be eligible if...** - You are between 18 and 65 years old - You have been diagnosed with rheumatoid arthritis - Your disease is moderately to highly active (as measured by a blood test and joint assessment) - You have been on a stable dose of standard arthritis medications for at least 3 months **You may NOT be eligible if...** - You are allergic to nicotinamide - You are already taking nicotinamide or vitamin B3 supplements - You are on biologic medications for rheumatoid arthritis - You have significant liver or kidney problems - You are pregnant or breastfeeding - You have another autoimmune disease Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.